Pirfenidone and mortality in idiopathic pulmonary fibrosis

Affiliations

¹ Section of Respiratory Diseases, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, via Giustiniani 3, 35128 Padova, Italy. Electronic address: paolo.spagnolo@unipd.it.

Comment

Paolo Spagnolo. Lancet Respir Med. 2017 Jan.

. 2017 Jan;5(1):3-5.

doi: 10.1016/S2213-2600(16)30416-7. Epub 2016 Nov 19.

¹ Section of Respiratory Diseases, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, via Giustiniani 3, 35128 Padova, Italy. Electronic address: paolo.spagnolo@unipd.it.

No abstract available

Comment on

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Nathan SD, et al. Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Lancet Respir Med. 2017. PMID: 27876247